TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01751724
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation.
Study: NCT00696618
Drug: Fleet Enema
Normalized name: Fleet Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyper-osmolar preparation
Study: NCT02614118
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.
Study: NCT02614118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 45 minutes before root canal treatment
Study: NCT02493933
Drug: Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02225093
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT02511639
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole is formulated as tablets of 1 mg strength for oral administration. Letrozole is formulated as tablets of 2.5 mg strength for oral administration. Exemestane is formulated as tablets of 25 mg strength for oral administration.
Study: NCT00156117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03800667
Drug: Ascorbic Acid 1000 MG
Normalized name: ascorbic acid 1000 MG
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg ascorbic acid (Vitamin C) for 1 month post-op after an elective gynecological surgery.
Study: NCT01646775
Drug: epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: withold epidural fentanyl
Study: NCT02832037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01188811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation
Study: NCT00623506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for two weeks (placebo lead in), then:~Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)
Study: NCT00422019
Drug: AMG 102 at 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
Study: NCT03646123
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 by IV infusion
Study: NCT04353037
Drug: Group 1 HCQ
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled participants randomized in Group 1 receive the HCQ drug
Study: NCT04353037
Drug: Group 2 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled participants randomized in Group 2 will receive a placebo drug
Study: NCT01718119
Drug: r-hCG
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hCG(250mcg) injection subcutaneously
Study: NCT00006369
Drug: ERA-923
Normalized name: ALCOHOL 4 mL TOPICAL CLOTH [Bioserica ERA Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02023554
Drug: Theophylline with azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Theophylline(100mg,sustained release tablets). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 1 to day 7.~Drug:Azithromycin(250mg, capsules). Multi-dose of azithromycin(500mg,once daily) will administered at 8 pm from day 1 to day 7.
Study: NCT02023554
Drug: Theophylline alone
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Theophylline(100mg,sustained release tablet). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 8 to day 14.
Study: NCT00638495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is to be administered orally once daily, after supper in principle, for 28 days.
Study: NCT00141830
Drug: Methotrexate plus ERB-041 for 12 weeks
Normalized name: methotrexate 2.5 MG (12) (7.5 MG per Week) Oral Tablet Pack
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00141830
Drug: Placebo for 12 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00872417
Drug: first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT
Study: NCT00872417
Drug: second line ARV therapy (3TC+TDF+LPV/RTV)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
Study: NCT02595398
Drug: Sham Procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham procedure administered at 2 timepoints
Study: NCT01460342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.
Study: NCT01844141
Drug: 70% alcohol - 0.5% clorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the intervention group five rounds of 3 ml wash of 70% alcohol - 0.5% clorhexidine was used to irrigate the exposed area of the nail to neutralize any residual effect of phenol and found out how much residual phenol is still in the wound.
Study: NCT02435199
Drug: EMA401 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02435199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01689519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplied as tablets
Study: NCT03635749
Drug: Standard antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1: Aspirin 100-300mg/day + clopidogrel placebo~Day 2 - 90: Aspirin 100mg/day+ clopidogrel placebo
Study: NCT03635749
Drug: Immediate high-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 - 21：Atorvastatin calcium 80mg/day~Day 22 - 90：Atorvastatin calcium 40mg/day
Study: NCT03635749
Drug: Delayed high-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 - 3：Atorvastatin calcium placebo~Day 4 - 21：Atorvastatin calcium 40mg/day + Atorvastatin calcium placebo~Day 22 - 90：Atorvastatin calcium 40mg/day
Study: NCT01867762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
Study: NCT03692949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03692949
Drug: LY3451838
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose administered SC
Study: NCT00744393
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
Study: NCT02247258
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See arm/group descriptions
Study: NCT01987102
Drug: [6R] 5,10-methylenetetrahydrofolate (arfolitixorin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The enrolled patients will be treated according to the MAP schedule and will receive the study drug \[6R\] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate® dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort.
Study: NCT02247258
Drug: Azathioprine in case of endoscopic recurrence
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See arm/group descriptions
Study: NCT00758602
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to center's practice
Study: NCT02425254
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg intravenous solution for infusion
Study: NCT02425254
Drug: Intravenous saline 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride in order to ensure double-blinding
Study: NCT03987451
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide placebo s.c. given once-weekly for 48 weeks
Study: NCT01154738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 9/00 (same volume as in the lidocaine group)~start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00
Study: NCT02625389
Drug: Lipiodol® Ultra Fluid with surgical glues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipiodol® Ultra Fluid and surgical glue mixture may vary from 20 to 80% and should be administered via selective arterial catheterization only.
Study: NCT03632668
Drug: AD-2072 80/5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD-2072 80/5mg tablet
Study: NCT03632668
Drug: AD-2071 10/20mg + AD2072 80/5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD-2071 10/20 mg + AD-2072 80/5mg tablet
Study: NCT01543854
Drug: RLX030
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of RLX030 over 20 hrs
Study: NCT01543854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of placebo over 20 hours
Study: NCT04489368
Drug: Neo-Adjuvant Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-Adjuvant Chemotherapy, delivered concurrently with Neo-Adjuvant Radiotherapy.
Study: NCT00756743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules q12 hours for 10 days
Study: NCT03465345
Drug: Oligomeric Procyanidin Complex
Normalized name: procyanidin A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.
Study: NCT03259919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 tablets x 1 daily for the first week, and 2 tablets x 2 for the rest of the study period.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
Study: NCT01872819
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive 1 of 160 possible interventions
Study: NCT03050307
Drug: TAK-438 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 placebo-matching tablets
Study: NCT03050307
Drug: Bismuth-Containing Quadruple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
Study: NCT01560104
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00653068
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02488252
Drug: Semi-individualised Chinese Medicine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: A: Panax ginseng, Atractylodes macrocephala, Pinellia ternate, Pericarpium citri reticulatae, Herba Pogostemonis, Glycyrrhiza uralensis, Rehmannia-6 decoction~B: Cortex magnoliae officinalis, Atractylodes macrocephala, Common Floweringquince Fruit, Common Vladimiria Root, Tsaoko Amomum Fruit, Palmae Fruit, Radixaconiti laterlis perparata, Zingiber officinale Rosc., Glycyrrhiza uralensis, Rehmannia-8 decoction~C: Root of Pilose Asiabell, Astragalus membranaceus, Rehmannia glutinosa, Common Macrocarpium Fruit, Dioscorea opposita , Barbary Wolfberry Fruit, Cortex eucommiae, Chinese Angelica, Glycyrrhiza uralensis~D: Rehmannia-6 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb~E: Rehmannia-8 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb
Study: NCT02488252
Drug: Routine medical care (active comparator)
Normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
Study: NCT00653068
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT00653068
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00430027
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given 650 mg/m\^2 BID on days of ration therapy, 825 mg/m\^2 day 1-14, day 15-20 off x 4
Study: NCT02895100
Drug: PTG-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of PTG-100 by subject for a 12 week treatment period.
Study: NCT02895100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of Placebo capsules by subject for a 12 week treatment period.
Study: NCT00269295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.
Study: NCT00125229
Drug: Hypertonic Saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02535143
Drug: Taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 ml of commercially available taurine containing energy drink to be administered three hours after the last meal and half an hour prior to performing the second test cavity
Study: NCT00003282
Drug: EF5
Normalized name: Hb 76(EF5), Met-thr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02750488
Drug: BAY987517
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
Study: NCT04030026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo tablet (matching NAL ER BID) over a 3 week period.
Study: NCT01187485
Drug: Androderm® 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
Study: NCT01187485
Drug: Androderm® 5.0mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
Study: NCT00202969
Drug: S-1 plus CDDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 21 with a single dose of CDDP 60 mg/m2 will be administered as an 1- to 3-hour IV infusion following the morning dose of S-1 on Day 8. The combination therapy will be repeated every 5 weeks.
Study: NCT02959658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manufactured to mimic Dimethyl Fumarate capsules
Study: NCT00414648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo dose of 2 tablets per day for 1 year.
Study: NCT01187485
Drug: Androderm® 7.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
Study: NCT02045719
Drug: uncaria tomentosa (cat´s claw)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03414736
Drug: SAR425899
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study: NCT00001384
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01235949
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
Study: NCT00215345
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01056835
Drug: prostaglandin I2 analogue
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00733473
Drug: % 0.9 Saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children will receive 2 ml of nebulized saline 2 times a day up to 5 days
Study: NCT03201419
Drug: Placebo oral solution
Normalized name: Placebo Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manufactured to mimic experimental drug
Study: NCT03201419
Drug: Placebo ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manufactured to mimic experimental drug
Study: NCT01670721
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
Study: NCT01670721
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
Study: NCT00880100
Drug: Ultrase® MT12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrase® MT12 capsules will be given orally daily based on investigator's discretion to a maximum dose of 2,500 lipase units per kilogram (kg) body weight per meal or snack for 19 to 24 days during the treatment phase. Total maximum dose not to exceed 10,000 lipase units/kg/day.
Study: NCT02313584
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01431521
Drug: MK-4074 200 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks
Study: NCT01431521
Drug: Placebo for MK-4074
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 100-mg capsules, orally, BID for 4 weeks.
Study: NCT00486512
Drug: 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)
Normalized name: calcium carbonate 1250 MG
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00486512
Drug: placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)
Normalized name: calcium carbonate 1250 MG
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01921283
Drug: no- BIS sensor attachment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01867502
Drug: MET + Glibenclamide Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). With the control the dose may be adjusted, reaching the maximum dose allowed, which is 20 mg / day.~For the glycemic control evaluation will be used the capillar glycemia at home. The adjustments will be done by the researcher coordinator.
Study: NCT00439296
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Treatment Course 1 only:~• 60 mg/m2/day IV over 15 minutes on day 1.
Study: NCT02389218
Drug: sequential drug adjustment (propafenone, sotalol or flecainide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone
Study: NCT00439296
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In Treatment Course 1:~• Given Intrathecally on day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~In Treatment Course 2:~• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~In Treatment Course 3:~Intrathecally on day 1 at the age-defined dose
Study: NCT00439296
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
Study: NCT02637583
Drug: PCV13
Normalized name: pneumococcal 13-valent conjugate vaccine (PCV13) 0.5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 13-valent pneumococcal conjugate vaccine once
Study: NCT01209351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo